The results of the Phase I Safety and Immunogenicity Trial of Recombinant HIV-1 Tat (ISS P-001 and ISS T-001) indicate that the vaccine based on the recombinant Tat protein is safe, well tolerated and immunogenic. The present study is intended to extend the follow-up of the volunteers for additional 3 years to evaluate the persistence of the anti-Tat humoral and cellular immune response. The results of the present study will be key for the design of future phase II trials, particularly for the definition of the optimal schedule for boosting immunizations. All individuals (20) will be enrolled in a 120-weeks observational study and monitored every 24 weeks for the following 3 years. During these visits, in addition to the hematological and biochemical assessment, the anti-Tat specific humoral and cellular immune responses will be evaluated.
Study Type
OBSERVATIONAL
Enrollment
5
San Raffaele Hospital
Milan, Italy
I.R.C.C.S. Spallanzani Hospital
Rome, Italy
Istituto Dermatologico S. Gallicano-IRCCS
Rome, Italy
To evaluate the persistence of specific immune responses, volunteers will be monitored for anti-Tat specific antibodies, anti-Tat proliferative response and in vitro γIFN and IL-4 production in response to Tat (Elispot).
To develop test procedures in order to evaluate humoral and cellular anti-Tat immunity for future efficacy trials.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.